UNSPSC 51285100: Combination H. pylori agents

This classification denotes combination drugs and preparations that combat a spiral, gram-negative, urease-positive bacterium active as a human gastric pathogen of genous helicobacter, and which therefore bears the name HELICOBACTER PYLORI or H. PYLORI, and which therefore constitute H. PYLORI AGENTS. Typical combination H. pylori agent constituents are clarithromycin and metronidazole.

UNSPSC 51285100 Combination H. pylori agents is a Class code that does not align with the recent state and local procurement activity tagged under it. The code nominally covers pharmaceutical agents targeting Helicobacter pylori infection; however, the four most recent opportunities posted under this code solicit naloxone and drug deactivation systems, medical and first aid supplies for fire rescue operations, generic multi-source pharmaceuticals and OTC products through cooperative purchasing, and direct-to-manufacturer prescription fulfillment capabilities. None of these procurements target H. pylori treatments specifically. The mismatch suggests either a taxonomy classification error in the source data or a state and local coding practice that does not align the UNSPSC assignment to the actual commodity scope.

The recent opportunities do show activity across multiple issuing-body types: Seminole County, Florida (a county health agency); the City of Tampa (municipal fire-rescue); the Texas Health and Human Services Commission (a state health agency); and the Minnesota Multistate Cooperative Purchasing Alliance (a multi-state cooperative vehicle administered by Minnesota). Geographic spread includes Florida, Texas, Minnesota, and Oregon. Representative recent opportunities include Seminole County's IFB for naloxone and drug deactivation systems (response due July 26, 2023), the City of Tampa's IFB for medical and first aid supplies for fire rescue ($700,000 estimated contract, response due March 13, 2026), Minnesota's RFP for generic pharmaceuticals and OTC products through MMCAP (response due March 26, 2026), and Texas HHS's RFI regarding direct-to-manufacturer prescription programs (response due April 3, 2026). Given the fundamental mismatch between the H. pylori code and the actual work being solicited, this code shows little decision-relevant recent activity for firms targeting treatment-specific pharmaceutical procurement.